Multiple sclerosis immunomodulatory therapies tested for effectiveness in COVID-19
| Autor: | Bożena Adamczyk, Monika Baran, Natalia Morawiec, Monika Arendarczyk, Krzysztof Wierzbicki, Paweł Sowa, Monika Adamczyk-Sowa |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Drug
medicine.medical_specialty Multiple Sclerosis business.industry SARS-CoV-2 Multiple sclerosis media_common.quotation_subject COVID-19 Disease medicine.disease Fingolimod Clinical trial Immunomodulation Respiratory failure Pandemic medicine Humans Surgery Neurology (clinical) Intensive care medicine business Pandemics medicine.drug media_common Leflunomide |
| Zdroj: | Neurologia i neurochirurgia polska. 55(4) |
| ISSN: | 0028-3843 |
| Popis: | Introduction: The global pandemic of COVID-19 began in Wuhan, China in December 2019. Research into effective therapies has been conducted worldwide. Currently, there is no antiviral treatment and many patients develop a severe course of the disease, including severe respiratory failure. Due to similar pathomechanisms of inflammation in multiple sclerosis (MS) and COVID-19, immunomodulatory drugs that are registered for the treatment of MS are under study in the SARS-CoV-2 infection in clinical trials. Materials and methods: Using clinicaltrials.gov, we found information related to ongoing clinical studies on potential drugs for COVID-19 which are also used in MS therapy. The outcomes of several trials were published on pubmed.ncbi.nlm.nih.gov. Results: There were 18 clinical trials evaluating the effectiveness and safety of interferon-β, fingolimod, or leflunomide in COVID-19. Some trial outcomes available at pubmed.ncbi.nlm.nih.gov suggested an association of these drug treatments with improvements in signs and symptoms, and the disease course. Conclusion: The administration of immunomodulatory drugs in COVID-19 may result in potential beneficial effects probably associated with their anti-inflammatory and antiviral properties. Further research is warranted to confirm the long-term effects of immunomodulatory therapies in patients with COVID-19. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|